MacroGenics, Inc. (MGNX)
MGNX Stock Price Chart
Explore MacroGenics, Inc. interactive price chart. Choose custom timeframes to analyze MGNX price movements and trends.
MGNX Company Profile
Discover essential business fundamentals and corporate details for MacroGenics, Inc. (MGNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Oct 2013
Employees
341.00
Website
https://www.macrogenics.comCEO
Scott Koenig
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Financial Timeline
Browse a chronological timeline of MacroGenics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.43, while revenue estimate is $28.72M.
Earnings released on 14 Aug 2025
EPS came in at -$0.57 surpassing the estimated -$0.59 by +3.39%, while revenue for the quarter reached $22.24M , missing expectations by -8.89%.
Earnings released on 13 May 2025
EPS came in at -$0.65 falling short of the estimated -$0.61 by -6.56%, while revenue for the quarter reached $13.19M , beating expectations by +12.11%.
Earnings released on 20 Mar 2025
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%, while revenue for the quarter reached $17.73M , missing expectations by -48.12%.
Earnings released on 5 Nov 2024
EPS came in at $0.90 surpassing the estimated $0.21 by +328.57%, while revenue for the quarter reached $110.71M , beating expectations by +238.67%.
Earnings released on 6 Aug 2024
EPS came in at -$0.89 falling short of the estimated -$0.47 by -89.36%, while revenue for the quarter reached $10.80M , missing expectations by -40.74%.
Earnings released on 9 May 2024
EPS came in at -$0.84 falling short of the estimated -$0.67 by -25.37%, while revenue for the quarter reached $9.10M , missing expectations by -38.74%.
Earnings released on 7 Mar 2024
EPS came in at -$0.75 falling short of the estimated -$0.26 by -188.46%, while revenue for the quarter reached $10.72M , missing expectations by -67.15%.
Earnings released on 6 Nov 2023
EPS came in at -$0.52 falling short of the estimated -$0.11 by -392.89%, while revenue for the quarter reached $10.40M , missing expectations by -69.55%.
Earnings released on 9 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.52 by +30.77%, while revenue for the quarter reached $13.14M , missing expectations by -55.83%.
Earnings released on 9 May 2023
EPS came in at -$0.61 falling short of the estimated $1.07 by -157.01%, while revenue for the quarter reached $24.21M , missing expectations by -74.33%.
Earnings released on 15 Mar 2023
EPS came in at $0.21 surpassing the estimated $0.10 by +110.00%, while revenue for the quarter reached $71.18M , beating expectations by +21.09%.
Earnings released on 3 Nov 2022
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $41.73M , beating expectations by +42.52%.
Earnings released on 8 Aug 2022
EPS came in at -$0.67 surpassing the estimated -$0.97 by +30.93%, while revenue for the quarter reached $26.01M , beating expectations by +83.64%.
Earnings released on 3 May 2022
EPS came in at -$1.08 falling short of the estimated -$0.84 by -28.57%, while revenue for the quarter reached $10.67M , beating expectations by +34.38%.
Earnings released on 24 Feb 2022
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%, while revenue for the quarter reached $13.62M , missing expectations by -38.71%.
Earnings released on 2 Nov 2021
EPS came in at -$0.86 falling short of the estimated -$0.63 by -36.51%, while revenue for the quarter reached $15.58M , missing expectations by -58.15%.
Earnings released on 29 Jul 2021
EPS came in at -$0.66 falling short of the estimated -$0.28 by -135.71%, while revenue for the quarter reached $30.37M , beating expectations by +13.13%.
Earnings released on 29 Apr 2021
EPS came in at -$0.90 falling short of the estimated -$0.53 by -69.81%, while revenue for the quarter reached $16.07M , missing expectations by -42.50%.
Earnings released on 25 Feb 2021
EPS came in at $0.02 surpassing the estimated -$0.58 by +103.45%, while revenue for the quarter reached $51.75M , beating expectations by +86.40%.
Earnings released on 4 Nov 2020
EPS came in at -$0.66 surpassing the estimated -$0.92 by +28.26%, while revenue for the quarter reached $17.42M , missing expectations by -32.29%.
MGNX Stock Performance
Access detailed MGNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.